Ultrasound contrast agent developer Molecular Biosystems remains beset by heavy losses, despite signs of increasing market interest in its Optison ultrasound contrast agent. MBI, which announced a restructuring plan in November to reduce its high
Ultrasound contrast agent developer Molecular Biosystems remains beset by heavy losses, despite signs of increasing market interest in its Optison ultrasound contrast agent. MBI, which announced a restructuring plan in November to reduce its high cash-burn rate (SCAN 11/25/98), reported a net loss of $11.9 million during its fiscal third quarter (end-December), compared with a net loss of $5.9 million in the same period in 1997. Revenues were $2.2 million, compared with $1.4 million last year. Optison sales totaled $509,000 during the quarter.
The news wasn't all negative, however. The San Diego firm reported a 37% increase in end-user demand for Optison, representing the fourth straight quarter of growing acceptance and demand for the agent, according to MBI. This increased demand has not benefited the firm's financial results, as inventories already sold to the distribution channel were sufficient to meet the demand, according to the firm. If these sales rates continue to hold up, the company expects to have the initial inventories of Optison shipped by the quarter ending in June.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.